CYP3A4
ENSG00000160868
Target class
Enzyme
Chromosome
7
Approved drugs
2
Clinical candidates (approved and in development)
3
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- Yes
- Target name
- CYP3A4
- Gene name
- Cytochrome P450 family 3 subfamily A member 4
- Gene symbol
- CYP3A4
- Previous gene symbols
- CYP3A3
- Protein name
- Cytochrome P450 3A4 (EC 1.14.14.1) (1,4-cineole 2-exo-monooxygenase) (1,8-cineole 2-exo-monooxygenase) (EC 1.14.14.56) (Albendazole monooxygenase (sulfoxide-forming)) (EC 1.14.14.73) (Albendazole sulfoxidase) (CYPIIIA3) (CYPIIIA4) (Cholesterol 25-hydroxylase) (Cytochrome P450 3A3) (Cytochrome P450 HLp) (Cytochrome P450 NF-25) (Cytochrome P450-PCN1) (Nifedipine oxidase) (Quinine 3-monooxygenase) (EC 1.14.14.55)
- Gene biotype
- Protein coding
- Gene family
- Cytochrome P450 family 3
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 7
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 335.3
- Tissue specificity (Gini)
- 0.96
- Tissue specificity (tau)
- 0.996
- KEGG gene identifiers
- hsa:1576
- Protein interaction confidence
- 0.918991
- Protein interaction partners
- 116
- R-HSA-211945
- R-HSA-211981
- R-HSA-5423646
- R-HSA-9027307
- R-HSA-9749641
- R-HSA-9754706
- R-HSA-9757110
- End position
- 99784274
- Start position
- 99756959
- Chromosome
- 7
- Strand
- Reverse
- Endoplasmic reticulum membrane
- Single-pass membrane protein. Microsome membrane
- Single-pass membrane protein.
- Cytosol
Publication evidence
- PubMed 21576599
- Tissue specificity (tau)
- 0.996407
- Expression inequality (Gini)
- 0.960342
Expression in transcripts per million
- Liver
- 335.3
- Small Intestine - Terminal Ileum
- 48.25
- Pancreas
- 2.41
- Skin - Sun Exposed (Lower leg)
- 1.92
- Skin - Not Sun Exposed (Suprapubic)
- 1.9
Expression in transcripts per million
- Liver335.3
- Small Intestine - Terminal Ileum48.25
- Pancreas2.41
- Skin - Sun Exposed (Lower leg)1.92
- Skin - Not Sun Exposed (Suprapubic)1.9
- Testis1.03
- Adrenal Gland1.01
- Pituitary0.77
- Brain - Cerebellum0.49
- Cells - EBV-transformed lymphocytes0.36
- Esophagus - Mucosa0.31
- Colon - Transverse0.27
- Brain - Cerebellar Hemisphere0.27
- Breast - Mammary Tissue0.24
- Nerve - Tibial0.24
- Ovary0.22
- Vagina0.22
- Minor Salivary Gland0.22
- Kidney - Cortex0.21
- Cervix - Ectocervix0.21
- Adipose - Visceral (Omentum)0.2
- Colon - Sigmoid0.19
- Muscle - Skeletal0.17
- Adipose - Subcutaneous0.16
- Uterus0.15
And 29 more, listed on the interactive page.
- GO:0002933
- GO:0006629
- GO:0006706
- GO:0006805
- GO:0008202
- GO:0008209
- GO:0008210
- GO:0009822
- GO:0016098
- GO:0042178
- GO:0042359
- GO:0042369
- GO:0042572
- GO:0042573
- GO:0042759
- GO:0046222
- GO:0070989
- GO:0005737
- GO:0005789
- GO:0043231
- GO:0004497
- GO:0005496
- GO:0005506
- GO:0005515
- GO:0008395
- GO:0008401
- GO:0016491
- GO:0016712
- GO:0019825
- GO:0019899
- GO:0030343
- GO:0034875
- GO:0050591
- GO:0050649
- GO:0062181
- GO:0062187
- GO:0062188
- GO:0062189
- GO:0070576
- GO:0101020
- GO:0101021
- GO:0102320
regulation of catalytic activity
Studies
- biochemical: NVS_ADME_hCYP3A4, is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP3A4 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.
Biological samples
- cell-free
Evidence sourceregulation of transcription factor activity
- cell-based: LTEA_HepaRG_CYP3A4is one of 100 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.
- cell-based: LTEA_HepaRG_CYP3A4is one of 100 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.
Biological samples
- HepaRG, cell line
Evidence source
Related records
Trials (859)
- "OK 2004 Study" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects
- "The Once A Day Protease Inhibitor Regimens"
- 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection
- A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects
- A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants
- A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
- A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
- A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients
- A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS
- A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy
- A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.
- A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
- A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
- A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects
- A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
- A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers
- A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
- A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects
- A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study
- A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome
Drugs (3)
- Cobicistat Cytochrome P450 3A inhibitor
- Ritonavir Cytochrome P450 3A inhibitor
- Tabimorelin Cytochrome P450 3A4 inhibitor